Skip to content

Gregory Penner

Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures.  He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases. Connect with Dr. Penner on LinkedIn or for company updates, follow NeoVentures. Click here to get in touch with our team.

The Importance Of What Is Difficult To Measure

The Importance Of What Is Difficult To Measure: How NeoVentures’ Aptamarker Platform Is Setting New Standards in Protein Measurement

In year three of the French revolution, a law was enacted to realize the rallying cry, “un roi, une loi, un poids, et une mesure” (One king, one law, one weight, and one measure) and this became the introduction of the metric system. The one… Read More »The Importance Of What Is Difficult To Measure: How NeoVentures’ Aptamarker Platform Is Setting New Standards in Protein Measurement

"Scientist in lab coat examining a petri dish sample through a microscope in a laboratory setting.

Unleashing the Potential of Neomer Library: A Revolutionary Approach to Aptamer Characterization and Improvement

In the dynamic realm of molecular biology, the quest for enhancing diagnostic tools and therapeutic approaches is an ever-evolving journey. One significant breakthrough in this pursuit is the development of the Neomer library, an innovative platform that allows the utilization of identical sequences across various… Read More »Unleashing the Potential of Neomer Library: A Revolutionary Approach to Aptamer Characterization and Improvement

Scientist selecting aptamers in a lab.

Aptamarker Use Case: Navigating the Molecular Landscape: Aptamarkers as the Compass for Patient Stratification

Molecular Space Construction: NeoVentures Biotechnology’s Aptamarker platform leverages Aptamarker analysis to construct a molecular space, where individuals cluster based on unique biomolecular profiles. This space captures diversity in responses to diseases and allows for the nuanced exploration of different pathophysiological processes leading to the same… Read More »Aptamarker Use Case: Navigating the Molecular Landscape: Aptamarkers as the Compass for Patient Stratification

Female scientist in a laboratory carefully dispensing liquid into test tubes.

Unleashing the Power of Aptamarkers: A New Frontier in Disease Management

Revolutionary Biomarker Discovery: Aptamarker allows agnostic screening for biomarkers, transforming disease understanding. Enables patient stratification in clinical trials for enhanced safety and precision medicine. Predictive and Precise Drug Development: Predicts side effects and translates animal model findings for safer drug development. Maps drug binding sites… Read More »Unleashing the Power of Aptamarkers: A New Frontier in Disease Management

Disease Detection

Revolutionizing Disease Detection: NeoVentures Biotechnology’s Aptamarker Platform

Aptamarker Paradigm Shift: NeoVentures Biotechnology’s Aptamarker platform challenges the traditional approach to biomarker discovery by eliminating the need to first understand the cause of a disease. Revolutionizing Healthcare: Aptamarker enables the identification of disease biomarkers without the constraints of unraveling disease causation, leading to faster… Read More »Revolutionizing Disease Detection: NeoVentures Biotechnology’s Aptamarker Platform

Microscope and array of test tubes on a laboratory bench.

Revolutionizing Drug Level Detection: NeoVentures’ Neomer Aptamers Take the Lead

NeoVentures’ Neomer aptamer selection method replaces the traditional SELEX process, offering a closed and reproducible space for aptamer development, ensuring consistency in drug level detection. The inclusion of an in-silico immune tolerance step enhances Neomer aptamers’ specificity and selectivity, making them more precise in detecting… Read More »Revolutionizing Drug Level Detection: NeoVentures’ Neomer Aptamers Take the Lead

dropper and Petry dish

Aptamarker Use Case: Breaking Barriers – Aptamarkers Pave the Way for Seamless Translation from Animal Trials to Human Trials

Immune Tolerance Advantage of Aptamarkers: Aptamarkers overcome immune tolerance issues in traditional antibody development. Aptamarkers vs. Antibodies: A Quantitative Advantage: Broader recognition spectrum aligns the biomarker landscape in animal models more closely with the human context. Training Aptamarkers in Animal Trials: Aptamarkers can be trained… Read More »Aptamarker Use Case: Breaking Barriers – Aptamarkers Pave the Way for Seamless Translation from Animal Trials to Human Trials

en_CAEnglish